No Detail Found!

Her-2 Expression Status in Different Histopathological Grades of Urothelial Carcinoma

Author(s)
AYESHA IMTIAZ MALIK Department of Pathology, Niazi Medical & Dental College,Sargodha,Pakistan
RUKHSANA JABEEN Department of Anatomy, Niazi Medical & Dental College,Sargodha,Pakistan
ATTYA ZAHEER Department of Anatomy, Rashid Lateef Medical College,Lahore,Pakistan
NAZMA KIRAN Department of Pathology, Rai Medical College,Sargodha,Pakistan
NAZIA SIDDIQUE Department of Pathology, Aleem Medical College,Lahore,Pakistan
Abstract
Urothelial carcinoma is the predominant histological sub-type and accounts for 90% of human urinary bladder cancers. It is among the ten common malignancies of adults in Pakistan. Her-2 receptor modifications including mutations have been previously evaluated as one of the major players in carcinogenesis of urinary bladder's carcinoma arising from urothelium. The increase in expression of Her-2 receptor is seen in higher grade carcinomas along with muscle infiltration in comparison to tumors of lesser grade and not invading muscle layer. Aims and Objectives: To compare epidermal growth factor (Her-2) receptor expression status between high and low grade, infiltrative and non-infiltrating carcinoma of urinary bladder's urothelium. Materials and Methods: 50 cases with diagnosis of primary papillary urothelial carcinoma with variable stages and grades, from both genders and different ages, were selected using convenience sampling for current cross sectional study. Routined protocols opted for immunohistochemical staining to observe Her-2 expression in urothelial cancer trans-urethral resection specimen. If more than 10 percent of cells with positive circumferential complete, and intense membrane staining for Her-2 were taken as positive as assessed semi-quantitatively by using immuno-reactive scoring system designated by ASCO/CAP guidelines. Results: Patients having ages ranging from 42 to 95 years including 37 males and 13 females were selected for current study. Her-2 immunostaining revealed, positivity in 27 (54%) patients. Results interpreted showed more number of cases having higher grade (p= 0.0006) and infiltration (p = 0.0001) with Her-2 positivity. Conclusions: The current study showed significant amount of Her-2 positivity in greater grade and carcinomas possessing muscle invasion as compared to tumors of lower grade and those not invading muscle wall.
Publication Details
Page(s) 221-223
Published Journal: Pakistan Journal of Medical and Health Sciences, Volume: 16, Issue: 05, Year: 2022

Request the full text from PASTIC

Keywords
Low grade urothelial carcinoma, Her-2 receptor, Invasive papillary urothelial carcinoma
References
Siegel RL,Miller KD,Jemal A .2020 .. , 10(1) : 7-30.
. .. PMID: 31912902., : .
Idrees R,Fatima S,Abdul-Ghafar J .2018 .Cancer prevalence in Pakistan: a meta-analysis of various published studies to determine variation in cancer figures resulting from marked population heterogeneity in different parts of the country. World J Surg Oncol, 16(1) : 129-33.
. .. , : .
Goldblum JR,Lamps LW,Mckenney JK,Myers JL .2018 .Rosai and Ackerman's Surgical Pathology. , : 1066-1096.
Goldblum JR,Lamps LW,Mckenney JK,Myers JL .2018 .Rosai and Ackerman's Surgical Pathology. , : 1434-1529.
Li BT,Makker V,Buonocore DJ,Offin MD .2018 .A multi-histology basket trial of ado-trastuzumab emtansine in patients with HER2 amplified cancers. J Clin Oncol, 36 : 2502-11.
Scholl S,Beuzeboc P,Pouilart P.,Targeting P. .2001 .Her-2 in other tumor types. Annals Oncol, 12 : 81-85.
Koshkin VS,O'Donnell P,Yu EY,Grivas P .2019 .. Systematic Review: Targeting HER2 in Bladder Cancer. 1 Jan, : 1-12.
Kumar S,Prajapati O,Vaiphei K,Parmar KM,Sriharsha AS,Singh SK .2015 .Human epidermal growth factor receptor 2/neu overexpression in urothelial carcinoma of the bladder and its prognostic significance: Is it worth hype? South Asian J Cancer. , 10(3) : PMC4756484-330X.
Sarkis J,Alkassis M,Assaf J . .Human epidermal growth factor receptor 2 (HER2) and the future of bladder carcinoma. Arab J Urol., : .
.2020 .. 2020 Nov, 1835439(4) : 273-274.
. .. PMID: 33425393; PMCID: PMC7755410., : .
. .Overexpression of Epidermal Growth Factor Receptor (EGFR) and HER-2 in Bladder Carcinoma and Its Association with Patients' Clinical Features. 2018 Oct, 10 : PMC6190725-7185.
Mooso BA .2015 .The role of EGFR family inhibitors in muscle invasive bladder cancer: A review of clinical data and molecular evidence. J Urol, 193 : 19-29.
EK Rowinsky .2004 .The erbB family: Targets for therapeutic development against cancer and therapeutic strategies using monoclonal antibodies and tyrosine kinase inhibitors. Annu Rev Med, 55 : 433-57.
0

Citations

0

Downloads

62

Views